Skip to content
medical devices and technologies hero image
medical devices and technologies hero image

Medical Devices and Technologies

Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities

Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities.

Our team spans disciplines including intellectual property (contentious and non-contentious), regulatory, product liability, mergers and acquisitions, commercial transactions (including licensing and collaborations), and capital markets and finance matters.

Our international network ensures that we have a ready resource of expertise in a wide range of jurisdictions and that we are well positioned to advise on cross-border work. Our lawyers have been advising clients in the sector for many years and have developed a deep understanding of the issues affecting the industry. This ensures that we add value to any matter and there is no learning curve.

For example, our team has been closely following the current proposed changes to the European medical devices regulatory framework. We have also been tracking and advising our clients on regulatory issues in the context of emerging technologies such as device/drug combinations, medical apps and other “connected health” initiatives. In these areas we use our broad and interdisciplinary experience to help our clients navigate what may often be rapidly evolving or uncertain regulatory pathways and manage the risks of new product development.

Our clients in the medical devices sector include Biomet, Samsung, GE Healthcare, Johnson & Johnson, Fresenius, Covidien, St Jude Medical and Novartis.

News & insights

Close up of data screen with figures

News: 12 FEBRUARY 2021

Allen & Overy advises Biogroup on two high-yield bond issues and a new senior facilities agreement

PARIS – Biogroup, the leading private medical laboratory services group in France and Belgium, has successfully completed through its two main subsidiaries the issuance of EUR800million in aggregate…

Read more
City skyline

News: 01 FEBRUARY 2021

Allen & Overy continues to make gains with FTSE clients

In the Adviser Rankings 15th anniversary guide A&O is ranked 3rd for FTSE 100 with 23 clients, up from 17 in 2010, and A&O is one of only two magic circle firms to have grown their total stock market…

Read more
Euro note with china flag overlay

Publications: 11 JANUARY 2021

Will the EU-China Comprehensive Agreement facilitate investment by EU companies in China?

The European Union (EU) and the People’s Republic of China concluded the negotiations on their investment treaty, the EU/China Comprehensive Agreement on Investment (CAI), on 30 December 2020. 

Read more
Allen & Overy graphic

Publications: 21 DECEMBER 2020

Covid-19 coronavirus and global employment law: Managing your workforce throughout the pandemic – part 4

In the fourth in our series of webinars, members of Allen & Overy’s Global Employment team discussed the significant issues and challenges that employers need to prioritise in relation to managing and…

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2021

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.